MediSix Therapeutics Launches with USD$20M Series A Financing
May 14, 2018 19:00 ET
|
Lightstone Ventures
SINGAPORE, May 14, 2018 (GLOBE NEWSWIRE) -- MediSix Therapeutics Pte. Ltd., a development-stage cell therapy company creating novel therapeutics to target T-cell leukemia and lymphoma, today...
Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
April 10, 2018 07:00 ET
|
Rich Pharmaceuticals
BEVERLY HILLS, CA , April 10, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology,...
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
February 06, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A - Combination aligns with Actinium’s focus on improving bone marrow transplant access...
Actinium Pharmaceuticals Announces Rights Offering
February 01, 2018 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting
December 11, 2017 06:30 ET
|
Actinium Pharmaceuticals
69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 µCi/kg/fraction as a single agent Minimal extramedullary toxicities observed; No evidence...
Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
November 29, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Poster presentation to detail results from ongoing Phase 2 trial for Actimab-A, Actinium’s CD33 targeting ARC or Antibody Radio-Conjugate, designed to explore Actimab-A’s efficacy in patients newly...
Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform
November 14, 2017 08:00 ET
|
Actinium Pharmaceuticals
- AWE Program launched post successful demonstration of Actinium’s “Biobetter” capabilities as evidenced by superior experimental results with actinium-225 labeled daratumumab when compared to...
Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz
November 13, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast -...
Actinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-B
October 25, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Current clinical trial sites represent approximately one third of bone marrow transplant volume in the U.S. - Actinium to provide update on SIERRA clinical trial by year-end NEW YORK, Oct. 25,...
Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
September 20, 2017 07:30 ET
|
Actinium Pharmaceuticals
- Actinium is now a member of the ASBMT™ Corporate Council - Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy NEW YORK,...